Sunday, September 12, 2021
6:45 AM – 7:45 AM MT
Gaylord Rockies Hotel and Convention Center
ROOM: Colorado A
3700 North Gaylord Rockies Boulevard
Aurora, CO 80019
Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
This live satellite symposium consists of a presentation from an expert faculty and 3D animation technology on the role of SGLT2 inhibitors in the management of patients with diabetes, heart failure, and/or chronic kidney disease, including an overview of key clinical trials.
This educational activity is intended for endocrinologists, cardiologists, nephrologists, primary care physicians, hospitalists, physician assistants, nurse practitioners, pharmacists, certified diabetes educators, managed care HCPs, and other HCPs who care for patients with diabetes.
Upon completion of this program, attendees should be able to:
- Identify patients with T2DM, heart failure or chronic kidney disease who would benefit from an SGLT2 inhibitor
- Apply guidelines and scientific evidence to the management of cardiovascular and/or renal risk in patients with T2DM
- Explain the mechanism of action of SGLT-2 inhibitors in T2DM, heart failure, and chronic kidney disease
- Analyze clinical trial data on the use of SGLT2 inhibitors for managing cardiovascular and/or renal risk in patients with T2DM
In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
HFSA designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.0 contact hours.
The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.0 contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-21-007-L04-P. To earn credit, participants must complete the online evaluation for each presentation attended and submit their NABP ID and DOB (MMDD). Once evaluations are completed, CPE will be uploaded to CPE monitor within 60 days of the close of the activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]. Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]